Recognizing the sight of blood in urine, the most common first sign of bladder cancer, is often the impetus that leads people ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

Groundbreaking study published in The Journal of Molecular Diagnostics paves the way for noninvasive screening tools that improve patient comfort and outcomes Bladder cancer remains a major clinical ...

Cellens, a Boston, MA-based cancer diagnostics startup, has raised a $6.5 million seed round. The company is developing a mechanobiology and AI-driven platform, BioFeel, for non-invasive cancer ...

A retrospective cohort study suggested that people with color blindness may have a higher risk of mortality from bladder ...

Researchers at the University of Birmingham believe that a simple urine test could help to guide clinicians in the treatment of bladder cancer patients. Being able to reliably identify those patients ...

People with color blindness may be less able to spot an early sign of bladder cancer, making them likelier to be diagnosed ...

Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...

Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrence AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global ...